HUP0104088A3 - Use of sustained release ranolazine formulations - Google Patents

Use of sustained release ranolazine formulations

Info

Publication number
HUP0104088A3
HUP0104088A3 HU0104088A HUP0104088A HUP0104088A3 HU P0104088 A3 HUP0104088 A3 HU P0104088A3 HU 0104088 A HU0104088 A HU 0104088A HU P0104088 A HUP0104088 A HU P0104088A HU P0104088 A3 HUP0104088 A3 HU P0104088A3
Authority
HU
Hungary
Prior art keywords
sustained release
release ranolazine
ranolazine formulations
formulations
sustained
Prior art date
Application number
HU0104088A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0104088(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of HUP0104088A2 publication Critical patent/HUP0104088A2/hu
Publication of HUP0104088A3 publication Critical patent/HUP0104088A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HU0104088A 1998-09-10 1999-09-09 Use of sustained release ranolazine formulations HUP0104088A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (2)

Publication Number Publication Date
HUP0104088A2 HUP0104088A2 (hu) 2002-05-29
HUP0104088A3 true HUP0104088A3 (en) 2002-12-28

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0104088A HUP0104088A3 (en) 1998-09-10 1999-09-09 Use of sustained release ranolazine formulations
HU0103844A HU224215B1 (hu) 1998-09-10 1999-09-09 Késleltetett felszabadulású ranolazinkészítmények

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0103844A HU224215B1 (hu) 1998-09-10 1999-09-09 Késleltetett felszabadulású ranolazinkészítmények

Country Status (33)

Country Link
US (14) US6303607B1 (OSRAM)
EP (3) EP1096937B9 (OSRAM)
JP (2) JP3745621B2 (OSRAM)
KR (1) KR100475759B1 (OSRAM)
CN (2) CN1193757C (OSRAM)
AR (3) AR022085A1 (OSRAM)
AT (2) ATE217794T1 (OSRAM)
AU (4) AU760435B2 (OSRAM)
BR (2) BR9913626A (OSRAM)
CA (2) CA2342390C (OSRAM)
CY (1) CY2008020I2 (OSRAM)
CZ (2) CZ301375B6 (OSRAM)
DE (3) DE122008000065I1 (OSRAM)
DK (2) DK1109558T3 (OSRAM)
ES (2) ES2177346T3 (OSRAM)
FR (1) FR09C0001I2 (OSRAM)
GE (1) GEP20053420B (OSRAM)
HK (1) HK1044284B (OSRAM)
HU (2) HUP0104088A3 (OSRAM)
IL (6) IL141893A0 (OSRAM)
LU (1) LU91504I2 (OSRAM)
MX (2) MXPA01002598A (OSRAM)
NL (1) NL300371I2 (OSRAM)
NO (4) NO319434B1 (OSRAM)
NZ (2) NZ510384A (OSRAM)
PL (3) PL196668B1 (OSRAM)
PT (2) PT1096937E (OSRAM)
RU (2) RU2214233C2 (OSRAM)
SI (2) SI1096937T1 (OSRAM)
TR (2) TR200101261T2 (OSRAM)
TW (1) TWI241911B (OSRAM)
UA (2) UA67793C2 (OSRAM)
WO (2) WO2000013686A2 (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6528511B2 (en) * 2000-02-18 2003-03-04 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
AU2003246791A1 (en) * 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
JP4546824B2 (ja) * 2002-05-21 2010-09-22 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を処置する方法
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CA2616845A1 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
EP1998387B1 (en) * 2006-03-17 2015-04-22 Konica Minolta Holdings, Inc. Organic electroluminescent device, display and illuminating device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518181A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
KR20100033490A (ko) * 2007-05-31 2010-03-30 질레드 팔로 알토 인코포레이티드 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
CN101835761A (zh) * 2007-06-13 2010-09-15 奥斯拜客斯制药有限公司 取代的哌嗪
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
HK1200114A1 (en) 2011-09-21 2015-07-31 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176567A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Pharmaceutical compositions comprising vanoxerine and antianginal compounds, and methods of administration of the same for treating episodes of cardiac arrhythmia, maintaining normal sinus rhythm, preventing recurrence of cardiac arrhythmia, and treatment of chronic cardiac arrhythmia in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
CA3240614A1 (en) 2021-12-31 2023-07-06 Stuart Rich Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
ATE217794T1 (de) 2002-06-15
US20050153982A1 (en) 2005-07-14
NO2009005I1 (no) 2009-03-16
UA75027C2 (uk) 2006-03-15
US20040097514A1 (en) 2004-05-20
NO20011191L (no) 2001-04-30
IL175371A0 (en) 2006-09-05
SI1096937T1 (en) 2005-04-30
US6852724B2 (en) 2005-02-08
AR022085A1 (es) 2002-09-04
HUP0103844A2 (hu) 2002-04-29
AU744071B2 (en) 2002-02-14
US6303607B1 (en) 2001-10-16
CZ301341B6 (cs) 2010-01-20
SI1109558T1 (en) 2002-10-31
US20030099705A1 (en) 2003-05-29
LU91504I9 (OSRAM) 2019-01-02
WO2000013686A3 (en) 2000-07-06
US20030166659A1 (en) 2003-09-04
US6620814B2 (en) 2003-09-16
PL202207B1 (pl) 2009-06-30
KR20010089874A (ko) 2001-10-12
PL196668B1 (pl) 2008-01-31
KR100475759B1 (ko) 2005-03-10
CZ301375B6 (cs) 2010-02-03
EP1096937B9 (en) 2007-02-28
JP2002524416A (ja) 2002-08-06
AU2008207707A1 (en) 2008-09-25
TR200101262T2 (tr) 2001-12-21
CN1193757C (zh) 2005-03-23
CA2342390A1 (en) 2000-03-16
US6525057B2 (en) 2003-02-25
PL348249A1 (en) 2002-05-20
US20040029890A1 (en) 2004-02-12
UA67793C2 (uk) 2004-07-15
GEP20053420B (en) 2005-01-25
IL141892A (en) 2006-08-20
HUP0104088A2 (hu) 2002-05-29
PL196263B1 (pl) 2007-12-31
JP3745621B2 (ja) 2006-02-15
BR9913626A (pt) 2001-12-04
NO20011192L (no) 2001-04-30
IL180864A0 (en) 2007-07-04
MXPA01002598A (es) 2002-04-08
EP1096937B1 (en) 2004-12-29
ATE285774T1 (de) 2005-01-15
US20030100566A1 (en) 2003-05-29
EP1109558A2 (en) 2001-06-27
NO20011191D0 (no) 2001-03-08
CZ2001879A3 (cs) 2001-08-15
NZ510384A (en) 2002-10-25
US6503911B2 (en) 2003-01-07
NO319434B1 (no) 2005-08-15
HK1044284A1 (en) 2002-10-18
PT1109558E (pt) 2002-10-31
TWI241911B (en) 2005-10-21
NO20054324L (no) 2001-04-30
NO20011192D0 (no) 2001-03-08
IL141893A0 (en) 2002-03-10
US6617328B2 (en) 2003-09-09
IL141892A0 (en) 2002-03-10
RU2207856C2 (ru) 2003-07-10
HK1040060A1 (en) 2002-05-24
FR09C0001I1 (OSRAM) 2009-02-27
CZ2001880A3 (cs) 2001-08-15
CA2343376C (en) 2007-01-09
CA2342390C (en) 2006-08-29
US20060217397A1 (en) 2006-09-28
CN1211086C (zh) 2005-07-20
US20060147521A1 (en) 2006-07-06
DE122008000065I1 (de) 2009-04-09
US6864258B2 (en) 2005-03-08
CY2008020I1 (el) 2010-07-28
BR9913553A (pt) 2001-10-23
DE69901570T2 (de) 2003-01-09
JP2006096757A (ja) 2006-04-13
HK1044284B (zh) 2005-07-15
ES2234302T3 (es) 2005-06-16
IL141893A (en) 2008-08-07
CA2343376A1 (en) 2000-03-16
NL300371I2 (nl) 2009-10-01
WO2000013687A2 (en) 2000-03-16
US6562826B1 (en) 2003-05-13
DK1109558T3 (da) 2002-08-26
AR053440A2 (es) 2007-05-09
DE69922964T2 (de) 2005-12-08
PT1096937E (pt) 2005-04-29
NO2009005I2 (OSRAM) 2010-06-28
EP1096937A2 (en) 2001-05-09
HUP0103844A3 (en) 2002-11-28
DK1096937T3 (da) 2005-05-09
AU760435B2 (en) 2003-05-15
NL300371I1 (nl) 2009-02-02
WO2000013687A3 (en) 2000-06-29
AU6142599A (en) 2000-03-27
DE69901570D1 (de) 2002-06-27
FR09C0001I2 (OSRAM) 2009-12-18
AU6036499A (en) 2000-03-27
DE69922964D1 (de) 2005-02-03
AR052921A1 (es) 2007-04-11
ES2177346T3 (es) 2002-12-01
CN1321088A (zh) 2001-11-07
CN1354665A (zh) 2002-06-19
EP1527779A1 (en) 2005-05-04
NO320986B1 (no) 2006-02-20
AU2008207703A1 (en) 2008-09-25
US20020090396A1 (en) 2002-07-11
CY2008020I2 (el) 2010-07-28
RU2214233C2 (ru) 2003-10-20
MXPA01002599A (es) 2005-02-17
US6369062B1 (en) 2002-04-09
US20050059667A1 (en) 2005-03-17
EP1109558B1 (en) 2002-05-22
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
HU224215B1 (hu) 2005-06-28
LU91504I2 (fr) 2009-02-03
TR200101261T2 (tr) 2002-05-21
NZ510386A (en) 2003-08-29
US20020004506A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
HUP0104088A3 (en) Use of sustained release ranolazine formulations
HUP0103883A3 (en) New sustained release oral formulations
IL151575A0 (en) Sustained release ranolazine formulations
PL343021A1 (en) Formulations
GB9715751D0 (en) Formulations
IL223035A0 (en) Extended release formulations of clarithromycin
IL178864A0 (en) 3'-prodrugs of 2'-deoxy-??-l-nucleosides
HRP20000707B1 (en) Sustained release preparations
IL135457A0 (en) Extended release formulation
EG22674A (en) Ectroparasiticidal aquequs suspension formulations
ZA9810710B (en) Sustained release formulations comprising alpha-glucosidase-inhibitors
GB9923045D0 (en) New oral formulations
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
GB9806312D0 (en) Novel formulations
GB9815002D0 (en) Formulations
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9815001D0 (en) Formulations
ZA982950B (en) Stabilized human papillomavirus formulations
GB9810181D0 (en) Novel formulations
GB9921062D0 (en) Use of cholestrol-lowering agent
GB9910118D0 (en) Formulations
GB9910667D0 (en) New use of citreamicins
GB9816563D0 (en) Controlled release formulations
GB9703099D0 (en) Formulations
GB9704521D0 (en) Formulations

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ROCHE PALO ALTO LLC, US

Free format text: FORMER OWNER(S): CV THERAPEUTICS, INC., US

HA9A Change in inventorship
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished